Objective To investigate the influencing factors of secondary diabetes mellitus after chemotherapy for hematologic tumors. Methods The medical records of 396 patients with hematologic tumors admitted to Jinhua People's Hospital from January 2018 to January 2024 were retrospectively analyzed. According to whether patients developed secondary diabetes mellitus during chemotherapy,they were divided into secondary diabetes mellitus group (n=127) and non-diabetes mellitus group (n=269). Transcriptome sequencing was used to explore the different signaling pathways between two groups. Multivariate Logistic regression analysis was used to screen the influencing factors of secondary diabetes mellitus after chemotherapy,and the prediction model of secondary diabetes mellitus after hematologic tumor chemotherapy was constructed. Results The common differential genes in bone marrow samples of two groups were mainly concentrated in vascular endothelial function regulation and vascular homeostasis pathway. There were significant differences in age,body mass index (BMI) and family history of diabetes mellitus,hypertension and hyperlipidemia,dexamethasone on conversion cumulative quantity,endothelin-1 (ET-1),vascular cell adhesion molecule 1 (VCAM-1),endothelial nitric oxide synthase (eNOS) between two groups (P<0.05). Multivariate Logistic regression analysis showed that age,BMI,history of hyperlipidemia,dexamethasone on conversion cumulative quantity,ET-1,VCAM-1 and eNOS were independent influencing factors for secondary diabetes mellitus in patients with hematologic tumors after chemotherapy (P<0.05). The area under the curve of predictive model was 0.844 (95％CI:0.806-0.883,P<0.001),indicating that the predictive ability of the model was good. Conclusion Age,BMI,combined hyperlipidemia,dexamethasone on conversion cumulative quantity,ET-1,VCAM-1 and eNOS are all independent influencing factors for secondary diabetes mellitus in patients with hematologic tumors after chemotherapy,and the prediction model can be used as a tool for early clinical screening.

Objective To investigate the influencing factors of secondary diabetes mellitus after chemotherapy for hematologic tumors. Methods The medical records of 396 patients with hematologic tumors admitted to Jinhua People's Hospital from January 2018 to January 2024 were retrospectively analyzed. According to whether patients developed secondary diabetes mellitus during chemotherapy,they were divided into secondary diabetes mellitus group (n=127) and non-diabetes mellitus group (n=269). Transcriptome sequencing was used to explore the different signaling pathways between two groups. Multivariate Logistic regression analysis was used to screen the influencing factors of secondary diabetes mellitus after chemotherapy,and the prediction model of secondary diabetes mellitus after hematologic tumor chemotherapy was constructed. Results The common differential genes in bone marrow samples of two groups were mainly concentrated in vascular endothelial function regulation and vascular homeostasis pathway. There were significant differences in age,body mass index (BMI) and family history of diabetes mellitus,hypertension and hyperlipidemia,dexamethasone on conversion cumulative quantity,endothelin-1 (ET-1),vascular cell adhesion molecule 1 (VCAM-1),endothelial nitric oxide synthase (eNOS) between two groups (P<0.05). Multivariate Logistic regression analysis showed that age,BMI,history of hyperlipidemia,dexamethasone on conversion cumulative quantity,ET-1,VCAM-1 and eNOS were independent influencing factors for secondary diabetes mellitus in patients with hematologic tumors after chemotherapy (P<0.05). The area under the curve of predictive model was 0.844 (95％CI:0.806-0.883,P<0.001),indicating that the predictive ability of the model was good. Conclusion Age,BMI,combined hyperlipidemia,dexamethasone on conversion cumulative quantity,ET-1,VCAM-1 and eNOS are all independent influencing factors for secondary diabetes mellitus in patients with hematologic tumors after chemotherapy,and the prediction model can be used as a tool for early clinical screening.

Objective:To investigate the expression characteristics of phosphorylated enhancer of Zeste homolog 2(EZH2)in head and neck squamous cell carcinoma(HNSCC)and their effect on chemosensitivity.Methods:Fifty-three patients with HNSCC treated between January 2018 and March 2021 in Tianjin Medical University Cancer Institute&Hospital were selected.Expression levels of p-EZH2S21,p-STAT3Y705,HIF-1α,and Ki-67 in HNSCC tissues were analyzed by immunohistochemical staining.Western blot was used to detect p-EZH2S21 expression in HNSCC tissues and cell lines.HNSCC cell lines stably transfected with wild type(EZH2-WT)or S21 mutant EZH2(EZH2-S21A)were construc-ted.CCK8 and colony formation assays were performed to detect the effect of EZH2 and S21 phosphorylation on HNSCC cell proliferation and their sensitivity to cisplatin(DDP)and 5-fluorouracil(5-FU).Results:Elevated levels of p-EZH2S21 were observed in HNSCC tissues and positively correlated with p-STAT3Y705(P<0.05)and HIF-1α(P<0.01)levels.p-EZH2S21 level correlated positively with lymph node metastasis(P<0.000 5),T(P<0.05),N(P<0.000 1)and AJCC stages(P<0.05).In vitro experiments confirmed that EZH2 expression promoted cell prolifer-ation and attenuated chemosensitivity of HNSCC cells.Inhibition of p-EZH2S21 restored HNSCC cell sensitivity to DDP and 5-FU.Conclusions:p-EZH2S21 plays an important role in tumor progression in HNSCC,and phosphorylation at S21 is an important way for EZH2 to affect HNSCC cell proliferation and chemotherapy sensitivity.